MetaCap

Immutep (IMMP) vs Lite Strategy (LITS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Immutep (IMMP) has outperformed Lite Strategy (LITS) over the past year, gaining 80.8% versus a loss of 52.8%. Over five years, IMMP leads with a -8.5% price change compared with -98.5% for LITS. Lite Strategy is the larger company by market cap ($24.0 million vs $22.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMMP+80.81%LITS-52.79%
+375%+134%-107%
Nov 21, 20251 yearNov 20, 2026
IMMP-18.37%LITS-98.56%
+115%+3%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMMP versus LITS key metrics
MetricIMMPLITS
Share price$3.11$0.8026
Market cap$22.92M$23.99M
1-day change-9.06%-4.03%
YTD return+8.74%-39.20%
1-year return+80.81%-52.79%
5-year return-8.53%-98.46%
EPS (TTM)$-7.30$-1.38
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-71.15M
52-week high$70.60$1.99
52-week low$2.66$0.69
Distance from 52-week high-95.59%-59.67%
Analyst consensusnone—
Avg. price target upside+864.63%—
Average volume26.07K524.33K
Shares outstanding7.37M29.88M
Employees—5
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IMMP has outperformed LITS by 133.6 percentage points over the past year.

About Immutep

IMMP stock →

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations

About Lite Strategy

LITS stock →

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

IMMP vs LITS FAQ

Which is bigger, Immutep or Lite Strategy?

Lite Strategy (LITS) is larger, with a market capitalization of $23.99M compared with $22.92M for Immutep (IMMP).

Which stock has performed better over the past year, IMMP or LITS?

IMMP returned +80.81% over the past 12 months, compared with -52.79% for LITS (price return, excluding dividends). Past performance does not predict future results.

Are Immutep and Lite Strategy in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons